Program
olezarsen
Also written as “Olezarsen”, “Cyclosporine Capsules USP (Modified) 100 mg” and “ISIS 678354”.
Its studies are mostly in Hypertriglyceridemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ionis Pharmaceuticals | 114 open or running | phase 3since Sep 23, 2020 | Dec 1, 2017 | Mar 2027phase 3 · NCT05681351 |
| Panacea Biotec | 20 open or running | no phasesince Mar 2, 2010 | Mar 2, 2010 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2010First studies: 2 no phase studies in Healthy VolunteersNew to Panacea BiotecPanacea Biotec · NCT01080586, NCT01080560
- Dec 1, 2017Ionis Pharmaceuticals's first study: phase 2 study in HypertriglyceridemiaNew to Ionis PharmaceuticalsIonis Pharmaceuticals · NCT03385239 · 114 enrolled · United States, Canada
- Sep 23, 2020Phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT04568434 · 66 enrolled · United States, Canada, France and more
- Oct 4, 2021Phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05079919 · 617 enrolled · United States, Australia, Bulgaria and more
- Nov 11, 20212 phase 3 studies in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT05130450, NCT05185843
- Apr 26, 2022Phase 2 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05355402 · 154 enrolled · United States, Canada
- Sep 20, 2022Phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05552326 · 446 enrolled · United States, Argentina, Belgium and more
- Oct 11, 2022Phase 1 study in Healthy ParticipantsIonis Pharmaceuticals · NCT05579860 · 104 enrolled · United States
- Nov 2, 2022Phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05610280 · 1,478 enrolled · United States, Bulgaria, Canada and more
- Dec 25, 2022Phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05681351 · 885 enrolled · United States, Argentina, Australia and more
- Jul 10, 2026Phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT07727538 · 12 planned · United States
Ahead
- Mar 2027Primary completion: phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05681351
- Jun 2027Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT05185843
- Feb 2028Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT05130450
- Aug 2030Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT07727538
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07727538Familial hyperchylomicronemia syndrome · United States | 3 | Recruiting | Ionis Pharmaceuticals | Aug 2030 | 12 |
| NCT05681351Hypertriglyceridemia · United States, Argentina, Australia and more | 3 | Active, not recruiting | Ionis Pharmaceuticals | Mar 2027 | 885 |
| NCT05610280Hypertriglyceridemia · United States, Bulgaria, Canada and more | 3 | Completed | Ionis Pharmaceuticals | Aug 8, 2024 | 1,478 |
| NCT05579860Healthy Participants · United States | 1 | Completed | Ionis Pharmaceuticals | May 22, 2023 | 104 |
| NCT05552326Hypertriglyceridemia · United States, Argentina, Belgium and more | 3 | Completed | Ionis Pharmaceuticals | Dec 17, 2024 | 446 |
| NCT05355402Hypertriglyceridemia · United States, Canada | 2 | Completed | Ionis Pharmaceuticals | Mar 22, 2023 | 154 |
| NCT05185843Familial hyperchylomicronemia syndrome · United States, Canada, Sweden | 3 | Active, not recruiting | Ionis Pharmaceuticals | Jun 2027 | 24 |
| NCT05130450Familial hyperchylomicronemia syndrome · United States, Canada, France and more | 3 | Active, not recruiting | Ionis Pharmaceuticals | Feb 2028 | 60 |
| NCT05079919Hypertriglyceridemia · United States, Australia, Bulgaria and more | 3 | Completed | Ionis Pharmaceuticals | Oct 22, 2024 | 617 |
| NCT04568434Familial hyperchylomicronemia syndrome · United States, Canada, France and more | 3 | Completed | Ionis Pharmaceuticals | Jul 14, 2023 | 66 |
| NCT03385239Hypertriglyceridemia · United States, Canada | 2 | Completed | Ionis Pharmaceuticals | Nov 25, 2019 | 114 |
| NCT01080586Healthy Volunteers · India | – | Completed | Panacea Biotec | Sep 2007 | 36 |
| NCT01080560Healthy Volunteers · India | – | Completed | Panacea Biotec | Sep 2007 | 36 |
How it is read
Names in the registry
- “Olezarsen”, 10 entries
- “Cyclosporine Capsules USP (Modified) 100 mg”, 2 entries
- “ISIS 678354”, 1 entry
Conditions, from the studies’ own filings
- Hypertriglyceridemia, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.